[1] Euler US.Uber die spezifische blutdrucksenkende substanzdes menschlichen prosata-und samenblasensekretes[J].Klin Woschr, 1935;14:1182
[2] Bergstrom S, Ryhage R, Samuelesson B, et al.Prostaglandins and related factors.The structure of prostaglandin E1, F1A and F1B[J].J Biol Chem, 1963;238:3555-64
[3] Bergstrom S, Sjovall J.The isolation of prostaglandin E from sheep prostate glands[J].Acta Chem Scand, 1960;14:1701-5
[4] Kirtland S.Prostaglandin E1:A Review[J].Prostaglandins Leukot rienes Essent Fatty Acids, 1988;32:165-74
[5] Wespes E, Delcour C, Struyven J, et al.The erectile angle: objective criterio to evaluate the papaverine test in impotence[J].J Urol, 1987;138:1171
[6] Carlson LA, Eriksson I.Femoral-artery infusion of prostaglandin E1 in severe peripheral vascular disease[J].Lancet, 1973;1: 155
[7] Porst H.The rationale for prostaglandin E1 in erectile failure:a survey of worldwide experience[J].J Urol, 1996;155:802-15
[8] Roy AC, Adaikan PG, Sen DK, et al.Prostaglandin 15- hydroxydehydrogenase activity in human penile corpora cavemosa and its significance in prostaglandin-mediated penile erection[J].J Urol, 1989;64:180
[9] Van Ahlen H, Peskar B, Sticht G, et al.Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum[J].J Urol, 1994;151:1227-30
[10] Creutzig A, Caspary L.Prostanoids in therapy of peripheral arterial occlusive disease[J].Therapie, 1991;46:241-5
[11] Herdrich H, Breddin HK, Rudofsky G.Cardiopulmonary effects and safety of prostaglangin E1:A Review[J].Int J Angiol, 1994;3:160-8
[12] Cox J, Andreadis N, Bone R.Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome[J]. Am Rev Respir Dis, 1988;137:5-12
[13] Cawello W, Schweer H, Dietrich B.Pharmacokinetics of prostaglandin E1 and its main metobolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction[J].J Urol, 1997;158:1403-7
[14] Leas AP, Bryson HM, Balfour JA.Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction[J].Drugs Aging, 1996;8:56-74
[15] Linet O, Neff L.Intracavernous prostaglandin E1 in erectile dysfunction[J].Clin Investig, 1994;72:139-49
[16] Linet O, Ogrinc F.Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction[J].N Engl J Med, 1996;334:873-7
[17] Pharmacia &Upjohn.Caverject (Brand of Alprostadil for Injection)[J].Caverject prescribing information, 1998:9-10
[18] Paoletti R.Biochemistry and pharmacology of prostaglandin E1: introductory remarks[A].In:Prostaglandin E1 in Atherosclerosis[M].Springer-Verlag, 1986:3-7
[19] Kawasakin A.Effect of prostaglandin E1-cyclodextrin clathrate compound (PGE1-alpha CD) on the experimental model of acute arterial obstruction.Relating to its vasodilator and antiplatelet aggregation action[J].Oyo Yakuri, 1971;17:1043
[20] Lumley P.Comparison of the potencies of some prostaglandins as vasodilators in three vascular beds of the anaesthetised dog[J].Eur J Pharmacol, 1982;81:421
[21] Schror K, Smith EF.Ⅲ:Dictionary of Prostaglandins[M]. New York:Medikon-Verlag, 1990:100
[22] Sinzinger H.Inhibition of mitotic and proliferative activity of smooth muscle cells by prostaglandin E1[A].In:Sinzinger H, Rogatti W, eds.prostaglandin E1 in Atherosclerosis[M].New York:Spring-Verlag, 1986:39-48
[23] Rexroth W.Effekte von PGE1 aufhamodynamik und extremitatenstoffwechsel bei gesunden und patienten mit arterieller ver-schlusskrankheit stadium Ⅲ[J].IV VASA, 1985;14:220
[24] Blume J, Ruhlmann KU, Kiesewetter H.Clinical efficacy of intraarterial PGE1-infusion in intermittent claudication[A].In: Sinzinger H, Rogatti W, eds.prostaglandin E1 in Atherosclerosis[M].New York:Spring-Verlag, 1986:75-80
[25] Bruch HP, HorlM, Herold A.Prostaglandin E1 in arterial occlusive disease in stages Ⅲ and Ⅳ according to Fontaine[A]. In:Sinzinger H, Rogatti W, eds.Prostaglandin E1 Athrosclerosis[M].New York:Spring-Verlag, 1986:81-91
[26] Hach W, Zanke BW, Sauerwein G, et al.Treatment of stage Ⅱ b peripheral arterial occlusive disease with short-term intraarterial infusions of prostaglandin E1[A].In:Sinzinger H, Rogatti W, eds.Prostaglandin E1 in Atherosclerosis[M].New York:Spring-Verlag, 1986:66-74
[27] Herdrich H.Long-term intravenous infusion of PGE1 in peripheral arterial lood flow disorders:results of an open screeing study with patients in Fontaine' s stages Ⅲ and Ⅳ[A].In: Sinzinger H, Rogatti W, eds.Prostaglandin E1 in Atherosclerosis[M].New Youk:Spring-Verlag, 1986:92-8
[28] Moltz H.Eseries prostaglandins and arginine vasoprssin in the modulation of male sexual behavior[J].Neurosci Biobehav Rev, 1990;14:109
[29] Molderings GJ, van Ahlen H, Gothert M.Moldulation of noradrenaline release in human corpus cavernosum by presynaptic prostaglandin receptors[J].Int J Impot Res, 1992;4:19
[30] SaenZ de Tejada I, Moreland RB.Physiology of erection, pathophysiology of impotence and implications of PGE1 in the control of collagen synthesis in the corpus cavernosum[A].In: Goldstein I, Lue TF, eds.The role of alprostadil in the diagnosis and treatment of erectile dysfunction[M].Princetion:Excerpta Mdica Inc, 1993;卷:3-6
[31] Aversa A, Isidori.Penile pharmacotesting in diagnosing male erectile dysfunction:evidence for lack of accuracy and specificity[J].Int J Androl, 2002;52:6-10
[32] Belcaro G, Cesarone MR, Nicolaides AN, et al.Microcirculatory strdies in erectile disorders[J].Curr Med Res Opin, 2000;16:72-5
[33] Chandeck Montesa K.Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 Versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction[J].Actas Urol Esp, 1992;16:208-16
[34] Choi HK, Adimoelija A, Kim SC, et al.A dose-response study of alprostadil sterile powder (S.Po.)(Caverject)for the treatment of erectile dysfunction in Korean and Indonesian men[J].Int J Impot Res, 1997;9:45-51
[35] Isidori A, Aversa A, Fabbri A.Erectile dysfunction[J].Recenti Prog Med Jul-Aug, 1999;90:396-402
[36] Metro MJ, Broderick GA.Diabetes and vascular impotence: does insulin dependence increase the relative severity[J] ? Int J Impot Res, 1999;11:87-9
[37] Becher E, Borghi M, Momesso A, et al.Penile hemodynamic findings with a new topical formulation of alprostadil[J].J Urol, 2001;159:239
[38] Zhao D.Treatment of Erectile Dysfunction with PGE1 Cream[J].Nation J Andrology, 2000;4:238-40
[39] Guo YL, Zhu JC.Efficacy and safety of prostaglandin E1 (PGE1)cream in the treatment of erectile dysfunction[C].The 9th world meeting on Impotence Research in Perth, Australia, 2000:26-9 |
